Back to DashboardScheduled — March 18, 2026Scheduled — March 20, 2026Scheduled — April 10, 2026Scheduled — April 7, 2026
Congressional Health Watch Coalition
Healthcare PolicyDrug PricingMedicare/Medicaid
28 hearings tracked
6 positive
14 negative
2 conflict
NegativeSFC-2026-01 · Senate Finance Committee
Medicare Drug Pricing Oversight: IRA Implementation Progress
CMS methodology scrutiny may tighten negotiation caps. Coalition members with drugs on the negotiation list face further pressure on pricing frameworks.
ACTION: Prepare member testimony emphasizing innovation investment impact. Coordinate with Cassidy and Shaheen offices on small-biotech exemption language.
NegativeHEC-2026-01 · House Energy & Commerce Committee
FDA Accelerated Approval Reform: Post-Market Evidence Requirements
Multiple coalition members have products under accelerated approval. 180-day initiation mandate creates $45-80M cost pressure per drug.
ACTION: File coordinated public comments. Deploy patient-focused narrative highlighting rare disease impact with DeGette and Eshoo offices.
NegativeHAPP-2026-01 · House Appropriations — Labor, HHS Subcommittee
FY2027 HHS Budget Hearing: CMS, FDA, and NIH Appropriations
Budget hearing spotlight on CMS drug pricing savings creates political pressure for more aggressive negotiation policy. Potential for IRA expansion language.
ACTION: Monitor for budget reconciliation amendments. Brief coalition members on FY2027 CMS appropriations riders that could expand negotiation list.
PositiveSHELP-2026-01 · Senate HELP Committee
AI in Healthcare: FDA Regulation of AI-Enabled Medical Devices
Regulatory clarity for AI-enabled diagnostics and clinical decision support software benefits coalition members adopting digital health platforms.
ACTION: Submit written statement on FDA's proposed AI/ML action plan. Engage Cassidy and Sanders offices on innovation-preserving AI regulatory framework.